Wedbush Boosts Kura Oncology (NASDAQ:KURA) Price Target to $38.00

Kura Oncology (NASDAQ:KURA) had its target price raised by analysts at Wedbush from $36.00 to $38.00 in a research note issued on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush’s price objective indicates a potential upside of 282.29% from the company’s current price.

Several other research firms also recently commented on KURA. Oppenheimer set a $24.00 price objective on Kura Oncology in a report on Thursday, May 28th. CLSA set a $24.00 price target on Kura Oncology in a research report on Thursday, June 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kura Oncology in a research note on Friday, July 17th. Citigroup reiterated a “market outperform” rating on shares of Kura Oncology in a research report on Thursday, May 28th. Finally, Citizens Jmp restated a “market outperform” rating and issued a $24.00 target price on shares of Kura Oncology in a report on Monday, June 15th. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Kura Oncology currently has a consensus rating of “Moderate Buy” and an average price target of $25.62.

Kura Oncology Price Performance

Shares of Kura Oncology stock opened at $9.94 on Thursday. The firm has a market capitalization of $882.37 million, a PE ratio of -2.97 and a beta of 0.38. The company has a current ratio of 6.15, a quick ratio of 6.14 and a debt-to-equity ratio of 0.09. Kura Oncology has a 12 month low of $6.24 and a 12 month high of $12.49. The business’s 50-day moving average price is $10.15 and its 200-day moving average price is $9.31.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.77) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.11. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. The business had revenue of $20.87 million for the quarter, compared to analysts’ expectations of $20.16 million. Sell-side analysts forecast that Kura Oncology will post -3.45 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Mollie Leoni sold 84,929 shares of Kura Oncology stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total value of $834,002.78. Following the sale, the insider owned 182,345 shares in the company, valued at $1,790,627.90. The trade was a 31.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 7.60% of the stock is owned by insiders.

Institutional Trading of Kura Oncology

Several institutional investors and hedge funds have recently bought and sold shares of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Kura Oncology by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company’s stock worth $333,000 after acquiring an additional 2,977 shares during the period. Strs Ohio purchased a new position in shares of Kura Oncology in the 1st quarter valued at approximately $143,000. Legal & General Group Plc boosted its position in shares of Kura Oncology by 35.1% during the second quarter. Legal & General Group Plc now owns 72,910 shares of the company’s stock valued at $421,000 after purchasing an additional 18,930 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Kura Oncology by 13.0% during the second quarter. Rhumbline Advisers now owns 118,896 shares of the company’s stock valued at $686,000 after purchasing an additional 13,690 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in Kura Oncology by 244.5% in the second quarter. American Century Companies Inc. now owns 232,752 shares of the company’s stock worth $1,343,000 after purchasing an additional 165,189 shares during the period.

Kura Oncology News Roundup

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: KOMZIFTI momentum strengthened. The acute myeloid leukemia treatment generated $9.1 million in net product revenue, a 57% increase from the first quarter, while new patient starts rose 35% to approximately 115. This commercial growth suggests increasing adoption of Kura’s marketed product. Kura Oncology Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Financial results exceeded expectations. Kura reported a second-quarter loss of $0.77 per share, narrower than the $0.88–$0.89 analyst consensus, while revenue of $20.87 million topped expectations of approximately $20.16 million. The earnings beat may be contributing to the stock’s strength. Kura Oncology Reports Q2 Loss and Beats Revenue Estimates
• Positive Sentiment: Collaboration revenue is expected to provide additional support. Management outlined approximately $90 million to $110 million of collaboration revenue for 2027, improving the company’s medium-term financial visibility. Kura Outlines 2027 Collaboration Revenue
• Neutral Sentiment: Clinical catalysts remain longer term. Kura is targeting topline results from the KOMET-017 study in 2028, leaving investors dependent on commercial execution and collaboration revenue in the nearer term. Kura Oncology Q2 2026 Earnings Call Transcript
• Negative Sentiment: Kura remains deeply unprofitable. Despite beating estimates, the company posted a substantial quarterly loss, with a reported negative net margin of 411.19%. Continued operating losses could limit valuation upside until product and collaboration revenue scale further. Kura Oncology Q2 2026 Earnings Call Summary

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.